PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Inclusion Criteria:

• Man or woman at least 18 years old
• Diagnosis of metastatic colorectal cancer
• At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Paraffin-embedded tumor tissue from the primary tumor or metastasis available for

central analyse Exclusion Criteria:

• History or known presence of central nervous system (CNS) metastases
• History of another primary cancer, except: Curatively treated in situ cervical cancer,or Curatively resected non-melanoma skin cancer, or Other primary solid tumorcuratively treated with no known active disease present and no treatment administeredfor ≥ 5 years before randomization
• Prior chemotherapy or systemic therapy for the treatment of metastatic colorectalcarcinoma except: adjuvant fluoropyrimidine-based chemotherapy or priorfluoropyrimidine therapy administered solely for the purpose of radiosensitization
• Prior oxaliplatin therapy
• Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) ortreatment with small molecule EGFr inhibitors (eg, erlotinib)
• Clinically significant cardiovascular disease (including myocardial infarction,unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiacarrhythmia) 1 year prior to randomization History of interstitial lung disease (eg,pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease onbaseline chest computed tomography (CT) scan
• Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > Common terminology criteria (CTC) grade 2 [CTCAE version 3.0])
• Peripheral sensory neuropathy with functional impairment